GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bayer AG (XTER:BAYN) » Definitions » Cyclically Adjusted Price-to-FCF

Bayer AG (XTER:BAYN) Cyclically Adjusted Price-to-FCF : 4.69 (As of Jun. 05, 2025)


View and export this data going back to 1953. Start your Free Trial

What is Bayer AG Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Bayer AG's current share price is €25.32. Bayer AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €5.40. Bayer AG's Cyclically Adjusted Price-to-FCF for today is 4.69.

The historical rank and industry rank for Bayer AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XTER:BAYN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 3.41   Med: 11.48   Max: 30.29
Current: 4.58

During the past years, Bayer AG's highest Cyclically Adjusted Price-to-FCF was 30.29. The lowest was 3.41. And the median was 11.48.

XTER:BAYN's Cyclically Adjusted Price-to-FCF is ranked better than
95.69% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.58 vs XTER:BAYN: 4.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bayer AG's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €-1.428. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €5.40 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bayer AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bayer AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bayer AG Cyclically Adjusted Price-to-FCF Chart

Bayer AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.52 9.29 8.77 6.12 3.47

Bayer AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.35 4.92 5.68 3.47 4.09

Competitive Comparison of Bayer AG's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Bayer AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bayer AG's Cyclically Adjusted Price-to-FCF falls into.


;
;

Bayer AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bayer AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=25.32/5.40
=4.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Bayer AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.428/127.7792*127.7792
=-1.428

Current CPI (Mar. 2025) = 127.7792.

Bayer AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 1.633 100.417 2.078
201509 2.029 100.417 2.582
201512 1.161 99.717 1.488
201603 1.160 100.017 1.482
201606 1.685 100.717 2.138
201609 2.899 101.017 3.667
201612 2.075 101.217 2.620
201703 0.489 101.417 0.616
201706 2.075 102.117 2.596
201709 2.432 102.717 3.025
201712 1.526 102.617 1.900
201803 0.349 102.917 0.433
201806 1.945 104.017 2.389
201809 1.420 104.718 1.733
201812 1.878 104.217 2.303
201903 0.698 104.217 0.856
201906 1.163 105.718 1.406
201909 1.581 106.018 1.906
201912 2.217 105.818 2.677
202003 -0.631 105.718 -0.763
202006 1.862 106.618 2.232
202009 1.443 105.818 1.742
202012 -0.145 105.518 -0.176
202103 -3.149 107.518 -3.742
202106 1.531 108.486 1.803
202109 2.201 109.435 2.570
202112 1.940 110.384 2.246
202203 -1.094 113.968 -1.227
202206 1.582 115.760 1.746
202209 1.963 118.818 2.111
202212 1.768 119.345 1.893
202303 -4.088 122.402 -4.268
202306 -0.124 123.140 -0.129
202309 1.927 124.195 1.983
202312 4.694 123.773 4.846
202403 -2.642 125.038 -2.700
202406 1.814 125.882 1.841
202409 1.533 126.198 1.552
202412 3.968 127.041 3.991
202503 -1.428 127.779 -1.428

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bayer AG  (XTER:BAYN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bayer AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bayer AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bayer AG Business Description

Industry
Address
Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.